Effects of sulfaphenazole derivatives on cardiac ischemia-reperfusion injury: Association of cytochrome P450 activity and infarct size

Journal of Pharmacological Sciences

Volumn 113, Issue 4, 2010, Pages 335-342

  Ishihara, Yasuhiro ^a   Sekine, Masaya ^a   Hamaguchi, Ai ^a   Kobayashi, Yusuke ^a   Harayama, Takashi ^a   Nakazawa, Mikio ^b   Shimamoto, Norio ^a  

^a TOKUSHIMA BUNRI UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

Author keywords

Cytochrome P450; Heart ischemia reperfusion; Reactive oxygen species; Sulfaphenazole

Indexed keywords

ACETYLSULFAPHENAZOLE; CYTOCHROME P450; CYTOCHROME P450 2C9; DICHLOROSULFAPHENAZOLE; HYDROGEN PEROXIDE; HYDROXYL RADICAL; LIPID PEROXIDE; REACTIVE OXYGEN METABOLITE; SULFAPHENAZOLE; SUPEROXIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTRON SPIN RESONANCE; ENZYME ACTIVITY; ENZYME INHIBITION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; MALE; MICROSOME; NONHUMAN; REPERFUSION INJURY;

EID: 77956194813     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.10103FP     Document Type: Article

References (30)

1. Kloner RA, Przyklenk K, Whittaker P. Deleterious effects of oxygen radicals in ischemia/reperfusion. Resolved and unresolved issues. Circulation. 1989;80:1115-1127.
2. Becker LB. New concepts in reactive oxygen species and cardiovascular reperfusion physiology. Cardiovasc Res. 2004;61:461-470.
3. Sukmawan R, Yada T, Toyota E, Neishi Y, Kume T, Shinozaki Y, et al. Edaravone preserves coronary microvascular endothelial function after ischemia/reperfusion on the beating canine heart in vivo. J Pharmacol Sci. 2007;104:341-348.
4. Tada H, Kutsumi Y, Misawa T, Shimamoto N, Nakai T, Miyabo S. Effects of pretreatment with 2-O-octadecylascorbic acid, a novel free radical scavenger, on reperfusion-induced arrhythmias in isolated perfused rat hearts. J Cardiovasc Pharmacol. 1990;16:984-991.
5. Kato K, Terao S, Shimamoto N, Hirata M. Studies on scavengers of active oxygen species. 1. Synthesis and biological activity of 2-O-alkylascorbic acids. J Med Chem. 1988;31:793-798.
6. Bolli R, Jeroudi MO, Patel BS, Dubose CM, Lai EK, Roberts R, et al. Direct evidence that oxygen-derived free radicals contribute to postischemic myocardial dysfunction in the intact dog. Proc Natl Acad Sci U S A. 1989;86:4695-4699.
7. Myers ML, Bolli R, Lekich RF, Hartley CJ, Roberts R. Enhancement of recovery of myocardial function by oxygen free-radical scavengers after reversible regional ischemia. Circulation. 1985;72:915-921.
8. Sun JZ, Kaur H, Halliwell B, Li XY, Bolli R. Use of aromatic hydroxylation of phenylalanine to measure production of hydroxyl radicals after myocardial ischemia in vivo. Direct evidence for a pathogenetic role of the hydroxyl radical in myocardial stunning. Circ Res. 1993;73:534-549.
9. Werns SW, Shea MJ, Driscoll EM, Cohen C, Abrams GD, Pitt B, et al. The independent effects of oxygen radical scavengers on canine infarct size. Reduction by superoxide dismutase but not catalase. Circ Res. 1985;56:895-898.
10. Tao L, Gao E, Jiao X, Yuan Y, Li S, Christopher TA, et al. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation. 2007;115:1408-1416.
11. Chen JX, Zeng H, Tuo QH, Yu H, Meyrick B, Aschner JL. NADPH oxidase modulates myocardial Akt, ERK1/2 activation, and angiogenesis after hypoxia-reoxygenation. Am J Physiol Heart Circ Physiol. 2007;292:H1664-H1674.
12. Thompson-Gorman SL, Zweier JL. Evaluation of the role of xanthine oxidase in myocardial reperfusion injury. J Biol Chem. 1990;265:6656-6663.
13. Janero DR, Burghardt B, Lopez R, Cardell M. Influence of cardioprotective cyclooxygenase and lipoxygenase inhibitors on peroxidative injury to myocardial-membrane phospholipid. Biochem Pharmacol. 1989;38:4381-4387.
14. Zhao X, Chen YR, He G, Zhang A, Druhan LJ, Strauch AR, et al. Endothelial nitric oxide synthase (NOS3) knockout decreases NOS2 induction, limiting hyperoxygenation and conferring protection in the postischemic heart. Am J Physiol Heart Circ Physiol. 2007;292:H1541-H1550.
15. Kojda G, Harrison D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res. 1999;43:562-571.
16. Levraut J, Iwase H, Shao ZH, Vanden Hoek TL, Schumacker PT. Cell death during ischemia: relationship to mitochondrial depolarization and ROS generation. Am J Physiol Heart Circ Physiol. 2003;284:H549-H558.
17. Ishihara Y, Sekine M, Nakazawa M, Shimamoto N. Suppression of myocardial ischemia-reperfusion injury by inhibitors of cytochrome P450 in rats. Eur J Pharmacol. 2009;611:64-71.
18. Granville DJ, Tashakkor B, Takeuchi C, Gustafsson AB, Huang C, Sayen MR, et al. Reduction of ischemia and reperfusion-induced myocardial damage by cytochrome P450 inhibitors. Proc Natl Acad Sci USA. 2004;101:1321-1326.
19. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica. 1995;25:261-270.
20. Khan M, Mohan IK, Kutala VK, Kumbala D, Kuppusamy P. Cardioprotection by sulfaphenazole, a cytochrome p450 inhibitor: mitigation of ischemia-reperfusion injury by scavenging of reactive oxygen species. J Pharmacol Exp Ther. 2007;323:813-821.
21. Mancy A, Dijols S, Poli S, Guengerich P, Mansuy D. Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9. Biochemistry. 1996;35:16205-16212.
22. Ishihara Y, Sekine M, Hatano A, Shimamoto N. Sustained contraction and endothelial dysfunction induced by reactive oxygen species in porcine coronary artery. Biol Pharm Bull. 2008;31:1667-1672.
23. Ishihara Y, Shiba D, Shimamoto N. Enhancement of DMNQinduced hepatocyte toxicity by cytochrome P450 inhibition. Toxicol Appl Pharmacol. 2006;214:109-117.
24. Gavella M, Kveder M, Lipovac V, Jurasin D, Filipovi-Vincekovic N. Antioxidant properties of ganglioside micelles. Free Radic Res. 2007;41:1143-1150.
25. Basumallick L, Ji JA, Naber N, Wang YJ. The fate of free radicals in a cellulose based hydrogel: detection by electron paramagnetic resonance spectroscopy. J Pharm Sci. 2009;98:2464-2471.
26. Wada Y, Mitsuda M, Ishihara Y, Watanabe M, Iwasaki M, Asahi S. Important amino acid residues that confer CYP2C19 selective activity to CYP2C9. J Biochem. 2008;144:323-333.
27. Lin T, Pan K, Mordenti J, Pan L. In vitro assessment of cytochrome P450 inhibition: strategies for increasing LC/MS-based assay throughput using a one-point IC(50) method and multiplexing high-performance liquid chromatography. J Pharm Sci. 2007;96:2485-2493.
28. Thum T, Borlak J. Cytochrome P450 mono-oxygenase gene expression and protein activity in cultures of adult cardiomyocytes of the rat. Br J Pharmacol. 2000;130:1745-1752.
29. Zordoky BN, El-Kadi AO. H9c2 cell line is a valuable in vitro model to study the drug metabolizing enzymes in the heart. J Pharmacol Toxicol Methods. 2007;56:317-322.
30. Cheng KC, Schenkman JB. Testosterone metabolism by cytochrome P-450 isozymes RLM3 and RLM5 and by microsomes. Metabolite identification. J Biol Chem. 1983;258:11738-11744.